Clinical applications of fibroblast activation protein‐targeted theranostics in oncologic and nononcologic disease: Current status and future directions
Hao Fu,
Wei Guo,
Jingxiong Huang,
Hua Wu,
Haojun Chen
Affiliations
Hao Fu
Department of Nuclear Medicine and Minnan PET Center Xiamen Key Laboratory of Radiopharmaceuticals The First Affiliated Hospital of Xiamen University School of Medicine Xiamen University Xiamen Fujian China
Wei Guo
Department of Nuclear Medicine and Minnan PET Center Xiamen Key Laboratory of Radiopharmaceuticals The First Affiliated Hospital of Xiamen University School of Medicine Xiamen University Xiamen Fujian China
Jingxiong Huang
Department of Nuclear Medicine and Minnan PET Center Xiamen Key Laboratory of Radiopharmaceuticals The First Affiliated Hospital of Xiamen University School of Medicine Xiamen University Xiamen Fujian China
Hua Wu
Department of Nuclear Medicine and Minnan PET Center Xiamen Key Laboratory of Radiopharmaceuticals The First Affiliated Hospital of Xiamen University School of Medicine Xiamen University Xiamen Fujian China
Haojun Chen
Department of Nuclear Medicine and Minnan PET Center Xiamen Key Laboratory of Radiopharmaceuticals The First Affiliated Hospital of Xiamen University School of Medicine Xiamen University Xiamen Fujian China
Abstract Quinoline‐based fibroblast activation protein (FAP) inhibitor (FAPI)‐based positron emission tomography (PET) imaging and radioligand therapy (RLT) are being investigated for use in a wide variety of diseases, and recent results have been promising. This review summarizes the current status of FAPI radiopharmaceuticals in PET imaging of malignant tumors and benign conditions and compares their diagnostic efficacy with 18F‐fluorodeoxyglucose. In addition, we summarize the previously published FAP‐targeted RLT data and discuss its current clinical use and future potential. Our qualitative summary can inform future research directions, medical guidelines, and optimal clinical decision‐making.
